2. Search Result
Search Result
Results for "

Idiopathic

" in MedChemExpress (MCE) Product Catalog:

84

Inhibitors & Agonists

1

Screening Libraries

7

Peptides

7

Inhibitory Antibodies

5

Natural
Products

11

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139310
    GLPG2938

    		LPL Receptor Others
    GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis .
    GLPG2938
  • HY-B0674
    Ebastine
    2 Publications Verification

    LAS-W 090; RP64305

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research .
    Ebastine
  • HY-B0801A
    Fexofenadine hydrochloride
    4 Publications Verification

    MDL-16455 hydrochloride; Terfenadine carboxylate hydrochloride

    		 Histamine Receptor Inflammation/Immunology
    Fexofenadine (MDL-16455) hydrochloride is an orally active and nonsedative H1 receptor antagonist. Fexofenadine hydrochloride can be used in allergic rhinitis and chronic idiopathic urticarial research .
    Fexofenadine hydrochloride
  • HY-B0801
    Fexofenadine
    4 Publications Verification

    MDL-16455; Terfenadine carboxylate

    		 Histamine Receptor Inflammation/Immunology
    Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research .
    Fexofenadine
  • HY-135088
    Autotaxin-IN-4

    		Phosphodiesterase (PDE) Inflammation/Immunology
    Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis .
    Autotaxin-IN-4
  • HY-100657
    meta-Fexofenadine

    meta-MDL-16455; meta-Terfenadine carboxylate

    		 Drug Metabolite Inflammation/Immunology
    meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine . Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial .
    meta-Fexofenadine
  • HY-100657R
    meta-Fexofenadine (Standard)

    		Drug Metabolite Inflammation/Immunology
    meta-Fexofenadine (Standard) is the analytical standard of meta-Fexofenadine. This product is intended for research and analytical applications. meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine . Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial .
    meta-Fexofenadine (Standard)
  • HY-168521
    αvβ6-IN-1

    		Integrin Inflammation/Immunology
    αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis .
    αvβ6-IN-1
  • HY-B0674R
    Ebastine (Standard)

    		Histamine Receptor Inflammation/Immunology Endocrinology
    Ebastine (Standard) is the analytical standard of Ebastine. This product is intended for research and analytical applications. Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research .
    Ebastine (Standard)
  • HY-B0674S1
    Ebastine-d6

    LAS-W 090-d6; RP64305-d6

    		 Histamine Receptor Isotope-Labeled Compounds Inflammation/Immunology Endocrinology
    Ebastine-d6 is deuterated labeled Ebastine (HY-B0674). Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research .
    Ebastine-d6
  • HY-162630
    HDAC6-IN-44

    		HDAC Inflammation/Immunology
    HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis .
    HDAC6-IN-44
  • HY-147741
    DPPY

    		JAK Btk EGFR Inflammation/Immunology Cancer
    DPPY (compound 6) is a potent PTK inhibitor with IC50 values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .
    DPPY
  • HY-B0801S4
    Fexofenadine-d3-1

    MDL-16455-d3-1; Terfenadine carboxylate-d3-1

    		 Histamine Receptor Isotope-Labeled Compounds Inflammation/Immunology
    Fexofenadine-d3-1 fumarate is deuterated labeled Fexofenadine (HY-B0801). Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research .
    Fexofenadine-d3-1
  • HY-P99288
    FG-3019

    Pamrevlumab; Anti-Human CTGF Recombinant Antibody

    		 Apoptosis Cancer
    FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
    FG-3019
  • HY-151955
    TGFβ1-IN-3

    		TGF-β Receptor Inflammation/Immunology
    TGFβ1-IN-3 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-3 can be used for idiopathic pulmonary fibrosis (IPF) research .
    TGFβ1-IN-3
  • HY-151954
    TGFβ1-IN-2

    		TGF-β Receptor Inflammation/Immunology
    TGFβ1-IN-2 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-2 can be used for idiopathic pulmonary fibrosis (IPF) research .
    TGFβ1-IN-2
  • HY-117873
    KBP-7018

    		c-Kit RET PDGFR Infection
    KBP-7018 is a tyrosine kinase-selective inhibitor. KBP-7018 has potent inhibitory effects on c-KIT, PDGFR, and RET with IC50 values of 10 nM, 7.6 nM and 25 nM, respectively. KBP-7018 can be used for the research of idiopathic pulmonary fibrosis .
    KBP-7018
  • HY-117873A
    KBP-7018 hydrochloride

    		c-Kit RET PDGFR Infection
    KBP-7018 hydrochloride is a tyrosine kinase-selective inhibitor. KBP-7018 hydrochloride has potent inhibitory effects on c-KIT, PDGFR, and RET with IC50 values of 10 nM, 7.6 nM and 25 nM, respectively. KBP-7018 hydrochloride can be used for the research of idiopathic pulmonary fibrosis .
    KBP-7018 hydrochloride
  • HY-14184
    Macitentan
    Maximum Cited Publications
    10 Publications Verification

    ACT-064992

    		 Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan
  • HY-151976
    STAT3-IN-15
    1 Publications Verification

    		 STAT Inflammation/Immunology
    STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .
    STAT3-IN-15
  • HY-100619A
    BMS-986020 sodium
    5+ Cited Publications

    AM152 sodium

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020 sodium
  • HY-108741A
    Plecanatide acetate

    		Guanylate Cyclase Inflammation/Immunology
    Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .
    Plecanatide acetate
  • HY-100619
    BMS-986020
    5+ Cited Publications

    AM152

    		 LPL Receptor Metabolic Disease Inflammation/Immunology
    BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .
    BMS-986020
  • HY-B0944
    Pidotimod

    		Bacterial Inflammation/Immunology
    Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
    Pidotimod
  • HY-14184S
    Macitentan-d4

    ACT-064992-d4

    		 Isotope-Labeled Compounds Endothelin Receptor Apoptosis Cardiovascular Disease
    Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].
    Macitentan-d4
  • HY-138304
    CC-90001
    1 Publications Verification

    		 JNK Inflammation/Immunology
    CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .
    CC-90001
  • HY-B0164
    Mizolastine

    		Histamine Receptor Inflammation/Immunology
    Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
    Mizolastine
  • HY-B0164A
    Mizolastine dihydrochloride

    		Histamine Receptor Inflammation/Immunology
    Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
    Mizolastine dihydrochloride
  • HY-14184R
    Macitentan (Standard)

    		Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan (Standard)
  • HY-B0944R
    Pidotimod (Standard)

    		Bacterial Inflammation/Immunology
    Pidotimod (Standard) is the analytical standard of Pidotimod. This product is intended for research and analytical applications. Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
    Pidotimod (Standard)
  • HY-B0164R
    Mizolastine (Standard)

    		Histamine Receptor Inflammation/Immunology
    Mizolastine (Standard) is the analytical standard of Mizolastine. This product is intended for research and analytical applications. Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .
    Mizolastine (Standard)
  • HY-156297
    β5i-IN-1

    		Proteasome Inflammation/Immunology
    β5i-IN-1 is a potent and selective inhibitor of β5i with a IC50 of 8.463 nM. β5i-IN-1 releases TNF-α and IL-6 and influences the transcriptional activity of NF-κB. β5i-IN-1 can be used in study idiopathic pulmonary fibrosis .
    β5i-IN-1
  • HY-147742
    Thi-DPPY

    		JAK Inflammation/Immunology
    Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC50 values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .
    Thi-DPPY
  • HY-169177
    JNK-1-IN-4

    		JNK Inflammation/Immunology
    JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
    JNK-1-IN-4
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-147946
    PDE1-IN-4

    		Phosphodiesterase (PDE) Calcium Channel Inflammation/Immunology
    PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .
    PDE1-IN-4
  • HY-P99351
    Andecaliximab

    Anti-MMP9 Reference Antibody (andecaliximab)

    		 MMP Cancer
    Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
    Andecaliximab
  • HY-131274
    Fexofenadine Impurity F

    		Drug Metabolite Others
    Fexofenadine Impurity F is the impurity of Fexofenadine. Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial .
    Fexofenadine Impurity F
  • HY-135089
    Autotaxin-IN-5

    		Phosphodiesterase (PDE) Inflammation/Immunology
    Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis .
    Autotaxin-IN-5
  • HY-116617
    15-Keto Travoprost

    15-Keto Fluprostenol isopropyl ester

    		 Drug Metabolite Others
    15-Keto Travoprost (15-Keto Fluprostenol isopropyl ester) is a metabolite of Travoprost (HY-B0584). 15-Keto Travoprost shows stimulatory effect on the growth and thickening of the eyelashes .
    15-Keto Travoprost
  • HY-B0679S
    Lubiprostone-d7

    RU-0211-d7; SPI-0211-d7

    		 Chloride Channel Metabolic Disease
    Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].
    Lubiprostone-d7
  • HY-14184A
    Macitentan (n-butyl analogue)

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan (n-butyl analogue)
  • HY-P99466
    Begelomab

    SAND-26

    		 Dipeptidyl Peptidase Inflammation/Immunology
    Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .
    Begelomab
  • HY-B0801AS
    Fexofenadine-d10 hydrochloride

    MDL-16455-d10 hydrochloride; Terfenadine carboxylate-d10 hydrochloride

    		 Isotope-Labeled Compounds Histamine Receptor Inflammation/Immunology Endocrinology
    Fexofenadine-d10 (hydrochloride) is deuterium labeled Fexofenadine (hydrochloride). Fexofenadine hydrochloride (MDL-16455 hydrochloride), a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years)[1].
    Fexofenadine-d10 hydrochloride
  • HY-135053
    Autotaxin-IN-3

    		Phosphodiesterase (PDE) Inflammation/Immunology
    Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC50 of 2.4 nM, compound 33, sourced from patent WO2018212534A1 .
    Autotaxin-IN-3
  • HY-162929
    TP-DEA2

    		TGF-β Receptor Inflammation/Immunology
    TP-DEA2, a predictable-release Triptolide (HY-32735) prodrug, block Bleomycin-induced pulmonary fibrosis and inflammation. TP-DEA2 significantly inhibits α-SMA production .
    TP-DEA2
  • HY-B0674S
    Ebastine-d5

    		Histamine Receptor Inflammation/Immunology Endocrinology
    Ebastine-d5 is the deuterium labeled Ebastine. Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research[1][2].
    Ebastine-d5
  • HY-B0801S2
    Fexofenadine-d3

    MDL-16455-d3; Terfenadine carboxylate-d3

    		 Histamine Receptor Inflammation/Immunology
    Fexofenadine-d3 is the deuterium labeled Fexofenadine[1]. Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[2][3][4].
    Fexofenadine-d3
  • HY-B0801AR
    Fexofenadine hydrochloride (Standard)

    MDL-16455 hydrochloride (Standard); Terfenadine carboxylate hydrochloride (Standard)

    		 Histamine Receptor Inflammation/Immunology
    Fexofenadine (hydrochloride) (Standard) is the analytical standard of Fexofenadine (hydrochloride). This product is intended for research and analytical applications. Fexofenadine (MDL-16455) hydrochloride is an orally active and nonsedative H1 receptor antagonist. Fexofenadine hydrochloride can be used in allergic rhinitis and chronic idiopathic urticarial research .
    Fexofenadine hydrochloride (Standard)
  • HY-145358
    FAP-PI3KI1

    		PI3K Cancer
    FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .
    FAP-PI3KI1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: